# Pending Steps According to Project Outline

**Date**: November 17, 2025  
**Reference**: `Cerebral_Aneurysm_Genomics_Project.md` - Timeline & Execution Plan (8 Phases)

---

## 📊 PROJECT PHASE STATUS

### ✅ **Phase 1: Data Acquisition & Integration** (Weeks 1-2) - **COMPLETE**

**Status**: ✅ **DONE**

**Completed Tasks**:
- ✅ GWAS data downloaded (Bakker 2020)
- ✅ Blood RNA-seq (GSE159610) - downloaded and analyzed
- ✅ Tissue RNA-seq (GSE122897, GSE158558, GSE66238) - downloaded and analyzed
- ✅ GTEx reference data - accessed
- ✅ Differential expression analysis completed
- ✅ Pathway enrichment analysis completed
- ✅ Multi-omics visualization outputs created

**Output**: ✅ Integrated data matrix available

---

### ❌ **Phase 2: Polygenic Risk Score Development** (Weeks 2-3) - **NOT DONE**

**Status**: ❌ **CRITICAL - MISSING**

**Required Tasks**:
1. ❌ **Build Weighted PRS from 17 GWAS Loci**
   - Extract 17 risk variants from Bakker 2020 GWAS
   - Calculate PRS = sum(dosage × log(OR)) for each variant
   - Standardize PRS scores
   - **Output**: PRS scores for each patient/sample

2. ❌ **Develop Elastic Net PRS (Advanced)**
   - Use all SNPs from GWAS (not just 17 loci)
   - Train elastic net model
   - **Output**: Advanced PRS with better prediction

3. ❌ **Stratify Patients by Genetic Risk**
   - Low/Intermediate/High risk groups
   - Validate stratification
   - **Output**: Risk-stratified patient groups

**Expected Output**: PRS scores, validation AUC 0.75-0.80

**Blocking Issue**: ❌ **No genotype data available** - PRS calculation requires individual-level genotype data, which is not available in the downloaded datasets.

**Potential Solutions**:
- Use population-level PRS (if GWAS summary stats can be applied)
- Contact authors for genotype data
- Use proxy PRS from published studies

**Scripts Needed**:
- `build_polygenic_risk_score.py` - Main PRS builder
- `validate_prs_performance.py` - PRS validation

**Priority**: 🔴 **HIGH** - Required for Phase 5 (Multi-Omics Integration)

---

### 🟡 **Phase 3: Blood Transcriptomics Integration** (Weeks 4-5) - **PARTIALLY DONE**

**Status**: 🟡 **IN PROGRESS - Basic analysis done, signature incomplete**

**Completed Tasks**:
- ✅ Blood RNA-seq analysis (GSE159610) - downloaded and processed
- ✅ Differential expression analysis completed
- ✅ Blood signature genes identified

**Remaining Tasks**:
1. ⚠️ **Complete Rupture-Associated Gene Signature**
   - Identify 20-30 gene signature from blood RNA-seq
   - Cross-validate signature performance
   - **Output**: Validated blood signature (AUC 0.82-0.86) - **NOT ACHIEVED**

2. ⚠️ **Harmonize Multiple Blood Datasets**
   - Integrate GSE159610 with other blood datasets if available
   - Batch correction and normalization

**Current Status**:
- ✅ Blood DE analysis completed
- ⚠️ Blood signature validation AUC: Not yet calculated
- ⚠️ Target: AUC 0.82-0.86 - **NOT VALIDATED**

**Scripts Available**:
- ✅ `deseq2_blood_analysis.py` - Blood DE analysis
- ⚠️ Need: Blood signature validation script

**Priority**: 🟠 **MEDIUM-HIGH** - Needed for Phase 5

---

### ❌ **Phase 4: Endothelial Dysfunction Profiling** (Week 5) - **NOT DONE**

**Status**: ❌ **MISSING**

**Required Tasks**:
1. ❌ **Analyze scRNA-seq Aneurysm Tissue**
   - **BLOCKED**: Single-cell RNA-seq dataset not available (GSE186927 was incorrect)
   - Need alternative approach

2. ⚠️ **Alternative: Cell-Type Deconvolution**
   - Use CIBERSORT, xCell, or similar tools
   - Estimate endothelial cell proportions from bulk RNA-seq
   - Analyze endothelial-specific signatures
   - **Status**: ⚠️ **Script created but may need refinement**

3. ❌ **Identify EC-Specific Dysfunction Markers**
   - ANGPT2, ICAM1, VCAM1, THBS1, PERP
   - Compare expression in aneurysm vs control
   - Calculate EC dysfunction score
   - **Output**: EC dysfunction score, top 5 dysregulated genes

**Scripts Available**:
- ✅ `endothelial_dysfunction_analysis.py` - EC analysis script (created)
- ✅ `complete_ec_dysfunction_analysis.py` - Complete EC analysis
- ⚠️ **Status**: Scripts exist but may need validation

**Blocking Issue**: Single-cell data not available, using bulk RNA-seq with deconvolution

**Priority**: 🟠 **MEDIUM** - Needed for Phase 5

---

### 🟡 **Phase 5: Multi-Omics Integration** (Week 6) - **PARTIALLY DONE**

**Status**: 🟡 **IN PROGRESS - Framework complete, limited by missing data**

**Completed Tasks**:
- ✅ Integration framework created
- ✅ Model training scripts created
- ✅ Tissue-based features integrated (EC dysfunction, Inflammation, ECM)
- ✅ Risk stratification outputs created
- ✅ ROC curves for models created
- ✅ Feature importance analysis completed
- ✅ Pathway enrichment visualizations completed

**Remaining Tasks**:
1. ⚠️ **Combine All Data Layers**
   - PRS (genetic) - ❌ **BLOCKED** - No PRS data (Phase 2 incomplete)
   - Blood RNA signature (GSE159610) - 🟡 **Partial** - Analysis done, validation incomplete
   - Tissue transcriptomics - ✅ **DONE** - Rupture datasets analyzed
   - EC dysfunction markers - ⚠️ **Partial** - Scripts exist, may need refinement
   - Clinical factors - ❌ **BLOCKED** - Not available in metadata

2. ⚠️ **Build Integrated Prediction Model**
   - Gradient boosting classifier - ✅ **Done** - Models trained
   - Cross-validation - ✅ **Done**
   - Model evaluation - ✅ **Done** - But limited by missing features
   - **Output**: Integrated model with AUC 0.85-0.92 - ⚠️ **Currently ~0.65-0.93** (tissue model), but not full integration

3. ⚠️ **SHAP Interpretation**
   - Explain which factors drive predictions - ⚠️ **Script created but may need running**
   - Feature importance analysis - ✅ **Done**
   - **Output**: SHAP values and interpretations

4. ✅ **Risk Stratification**
   - Low/Intermediate/High risk categories - ✅ **Done**
   - Clinical decision thresholds - ✅ **Done**
   - **Output**: Risk-stratified predictions - ✅ **Complete**

**Current Status**:
- ✅ Integration framework: **Complete**
- ✅ Tissue model: **Working** (AUC ~0.93 for tissue, ~0.61-0.57 for blood)
- ⚠️ Full multi-omics integration: **Limited by missing PRS and blood signature**
- ⚠️ Target AUC 0.85-0.92: **Not achieved** (would require all data layers)

**Scripts Available**:
- ✅ `comprehensive_multi_omics_integration.py` - Main integration
- ✅ `build_full_multi_omics_model.py` - Full model builder
- ✅ `shap_interpretation.py` - SHAP analysis (may need running)
- ✅ `risk_stratification.py` - Risk categories (done)

**Priority**: 🔴 **HIGH** - Core innovation, but blocked by Phases 2-4

---

### ❌ **Phase 6: Exosomal Biomarker Discovery** (Week 7) - **NOT DONE**

**Status**: ❌ **NOT STARTED**

**Required Tasks**:
1. ❌ **Identify Novel Exosomal ncRNAs**
   - Analyze non-coding RNAs in blood data
   - Identify rupture-associated ncRNAs
   - Validate candidates

2. ❌ **Create Clinical Nomogram**
   - Combine integrated score + exosomal biomarkers
   - Create nomogram for clinical use
   - **Output**: Clinical nomogram

**Expected Output**: 10 novel biomarkers, nomogram

**Priority**: 🟢 **LOW** - Optional but valuable

**Status**: Not critical for main objectives, can be added later

---

### ❌ **Phase 7-8: Validation & Manuscript** (Weeks 8-12) - **NOT DONE**

**Status**: ❌ **NOT STARTED**

**Required Tasks**:
1. ❌ **External Validation**
   - Validate model on external dataset (if available)
   - Cross-dataset validation
   - **Status**: ⚠️ Limited by data availability

2. ❌ **Comparison with PHASES Score**
   - Calculate PHASES scores (if clinical data available)
   - Compare AUC: Integrated model vs PHASES
   - Demonstrate 20-30% improvement
   - **BLOCKED**: ❌ Clinical data not available

3. ✅ **Generate Publication-Quality Figures**
   - ROC curves - ✅ **Done**
   - Feature importance plots - ✅ **Done**
   - Pathway networks - ⚠️ **Partially done**
   - Risk stratification plots - ✅ **Done**

4. ❌ **Write Manuscript**
   - Methods section
   - Results section
   - Discussion
   - **Status**: ❌ **Not started**

**Expected Output**: Publication-ready manuscript

**Priority**: 🟡 **MEDIUM** - Final phase, but needs Phases 2-5 complete first

---

## 🚨 **CRITICAL PATH - IMMEDIATE PRIORITIES**

### **Priority 1: Complete Phase 2 (Polygenic Risk Score)** 🔴 **HIGHEST**

**Why Critical**: PRS is required for true multi-omics integration (Phase 5)

**Action Items**:
1. **Workaround**: If individual genotypes unavailable, use population-level PRS
   - Use GWAS summary statistics to calculate population-level PRS
   - Apply to samples based on ancestry/population
   - Create `build_population_prs.py`

2. **Alternative**: Contact authors or search for PRS from published studies

3. **Create scripts**:
   - `build_polygenic_risk_score.py` - Main PRS builder
   - `validate_prs_performance.py` - PRS validation

**Timeline**: 2-3 days

**Blocking**: Phase 5 (Multi-Omics Integration)

---

### **Priority 2: Complete Phase 3 (Blood Signature Validation)** 🟠 **HIGH**

**Why Critical**: Blood signature needed for multi-omics model

**Action Items**:
1. **Validate Blood Signature Performance**
   - Run cross-validation on blood signature
   - Calculate AUC for blood signature alone
   - Target: AUC 0.82-0.86

2. **Create blood signature score**
   - Calculate signature score from top genes
   - Validate on independent samples (if available)

**Scripts Needed**:
- `validate_blood_signature.py` - Blood signature validation

**Timeline**: 1-2 days

---

### **Priority 3: Complete Phase 4 (EC Dysfunction)** 🟠 **MEDIUM-HIGH**

**Why Critical**: EC dysfunction is third omics layer for integration

**Action Items**:
1. **Refine EC Dysfunction Analysis**
   - Run `complete_ec_dysfunction_analysis.py`
   - Validate EC dysfunction score
   - Identify top 5 dysregulated genes

2. **Alternative Approach (if scRNA-seq unavailable)**:
   - Use bulk RNA-seq with cell-type deconvolution
   - Calculate EC-specific scores

**Timeline**: 2-3 days

---

### **Priority 4: Complete Phase 5 (Full Multi-Omics Integration)** 🔴 **HIGHEST**

**Why Critical**: This is the core innovation - combining all layers

**Action Items**:
1. **Wait for Phases 2-4 completion** - Integration needs all components

2. **Once components available**:
   - Combine PRS + Blood + Tissue + EC dysfunction + Clinical
   - Train full gradient boosting model
   - Validate performance (target AUC 0.85-0.92)
   - SHAP interpretation (run `shap_interpretation.py`)
   - Final risk stratification

3. **Current capability**:
   - Can run with available tissue features only
   - AUC currently ~0.65-0.93 (depends on model)
   - Will improve when all layers integrated

**Timeline**: 3-4 days (after Phases 2-4 complete)

---

### **Priority 5: PHASES Score Comparison** 🟡 **MEDIUM**

**Status**: ⚠️ **BLOCKED - No Clinical Data**

**What's Needed**:
- Age, Sex, Hypertension status
- Aneurysm size
- Population (Finnish/Japanese/other)
- Early SAH history
- Site (anterior/posterior)

**Options**:
1. Extract from GEO series matrix (if available)
2. Contact authors (ij.m.ruigrok@umcutrecht.nl)
3. Check publication supplementary materials
4. **Skip if not available** (note limitation in manuscript)

**If data becomes available**:
- Create `phases_comparison.py` script
- Calculate PHASES scores
- Compare AUC: Your model vs PHASES
- Statistical testing (DeLong test, NRI, IDI)

**Timeline**: 2-3 days (if data available)

---

## 📋 **RECOMMENDED EXECUTION ORDER**

### **Immediate Next Steps (Week 1-2)**

1. ✅ **Phase 1**: Data Acquisition - **COMPLETE**
2. ❌ **Phase 2**: Build Polygenic Risk Score - **START HERE**
   - Workaround: Population-level PRS if genotypes unavailable
   - Timeline: 2-3 days
3. 🟡 **Phase 3**: Complete Blood Signature Validation - **IN PROGRESS**
   - Validate signature performance
   - Timeline: 1-2 days
4. ❌ **Phase 4**: Complete EC Dysfunction Analysis - **PARTIAL**
   - Refine existing scripts
   - Timeline: 2-3 days

### **Integration Phase (Week 3-4)**

5. 🟡 **Phase 5**: Full Multi-Omics Integration - **PARTIAL**
   - Combine all completed layers
   - Train integrated model
   - SHAP interpretation
   - Timeline: 3-4 days

### **Validation Phase (Week 5-6)**

6. ❌ **Phase 7-8**: Validation & Manuscript - **NOT STARTED**
   - PHASES comparison (if data available)
   - External validation
   - Publication figures (mostly done ✅)
   - Manuscript writing
   - Timeline: 2-3 weeks

### **Optional (Week 7)**

7. ❌ **Phase 6**: Exosomal Biomarker Discovery - **OPTIONAL**
   - Can be done in parallel or later
   - Timeline: 1 week

---

## 🎯 **SUCCESS CRITERIA (From Project Outline)**

### Required for Publication:

1. ❌ **PRS Development:** AUC 0.75-0.80 - **NOT DONE**
2. ⚠️ **Blood Signature:** AUC 0.82-0.86 - **NOT VALIDATED**
3. ⚠️ **Integrated Model:** AUC 0.85-0.92 - **PARTIAL** (tissue only, missing full integration)
4. ❌ **Improvement over PHASES:** 20-30% better - **CANNOT TEST** (no clinical data)
5. ⚠️ **EC Dysfunction Score:** Top 5 genes identified - **PARTIAL** (scripts exist)
6. ✅ **Risk Stratification:** Low/Intermediate/High categories - **DONE**

---

## 📊 **CURRENT CAPABILITIES VS PROJECT OUTLINE**

### ✅ **What We CAN Do Now**:
- ✅ Tissue-based rupture prediction (AUC ~0.93)
- ✅ Blood-based prediction (AUC ~0.57-0.61)
- ✅ Risk stratification with categories
- ✅ Feature importance analysis
- ✅ Pathway enrichment analysis
- ✅ Publication-quality figures (ROC, feature importance, pathways, risk)

### ❌ **What We CANNOT Do (Blocked by Missing Data)**:
- ❌ Full multi-omics integration (missing PRS)
- ❌ PRS calculation (no genotype data)
- ❌ PHASES comparison (no clinical data)
- ❌ External validation on independent cohort (no external dataset)
- ❌ Exosomal biomarker discovery (not started)

---

## 🔧 **TECHNICAL BLOCKERS**

### **Critical Blockers**:
1. ❌ **No Genotype Data** → Cannot calculate individual-level PRS
   - **Solution**: Use population-level PRS as workaround

2. ❌ **No Clinical Data** → Cannot calculate PHASES score
   - **Solution**: Contact authors or note as limitation

3. ⚠️ **Blood Signature Not Validated** → Performance unknown
   - **Solution**: Run validation script

### **Data Limitations**:
- ✅ Tissue data: **Available** (GSE122897)
- ✅ Blood data: **Available** (GSE159610)
- ❌ Genotype data: **Not available**
- ❌ Clinical data: **Not in metadata**
- ❌ Single-cell data: **Not available** (using bulk with deconvolution)

---

## 📝 **SUMMARY**

### **Completed (✅)**:
- Phase 1: Data Acquisition & Integration
- Phase 3: Blood Transcriptomics (basic analysis)
- Phase 5: Multi-Omics Integration (tissue-based, framework complete)
- Phase 7-8: Publication figures (mostly complete)

### **In Progress (🟡)**:
- Phase 3: Blood signature validation
- Phase 4: EC dysfunction analysis (scripts exist)
- Phase 5: Full multi-omics integration (waiting for Phases 2-4)

### **Not Started (❌)**:
- Phase 2: Polygenic Risk Score (blocked by no genotypes)
- Phase 6: Exosomal biomarker discovery (optional)
- Phase 7-8: Manuscript writing, PHASES comparison

### **Immediate Next Step**: 
**Build Polygenic Risk Score (Phase 2)** - Use population-level PRS as workaround

---

**Last Updated**: November 17, 2025  
**Status**: Following project outline phases 1-8  
**Next Critical Action**: Phase 2 (PRS) - Required for Phase 5 completion

